This is the new MLex platform. Existing customers should continue to access MLex here until migrated to the new platform. For any migration queries, please contact Customer Services or your Account Manager.

Edwards’ JenaValve deal could strengthen market position, remove potential competition, Austrian regulator says

( October 29, 2024, 17:58 GMT | Official Statement) -- MLex Summary: Edwards Lifesciences’s takeover of JenaValve Technology could strengthen its “already strong” position in the market for valves for treating aortic regurgitation and aortic stenosis, the Austrian competition authority said today in announcing its decision to refer the deal for an in-depth probe. The deal also raises competition concerns about removing the “only potential competitor” to Edwards as it would combine the world’s only approved valves for treating aortic regurgitation, the authority said. It said the deal could make it more difficult for other companies to enter the market, citing high barriers to entry in the form of intellectual property rights....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login